Antisense modulation of Beta catenin expression
DCFirst Claim
1. An antisense compound 8 to 30 nucleobases in length targeted to a 3'"'"'-untranslated region, a start codon, a coding region from nucleobases 276-2450, a stop codon or a 5'"'"'-untranslated region of human Beta catenin, wherein said antisense compound specifically hybridizes with and inhibits the expression of human Beta catenin.
2 Assignments
Litigations
0 Petitions
Accused Products
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of Beta catenin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Beta catenin. Methods of using these compounds for modulation of Beta catenin expression and for treatment of diseases associated with expression of Beta catenin are provided.
49 Citations
20 Claims
- 1. An antisense compound 8 to 30 nucleobases in length targeted to a 3'"'"'-untranslated region, a start codon, a coding region from nucleobases 276-2450, a stop codon or a 5'"'"'-untranslated region of human Beta catenin, wherein said antisense compound specifically hybridizes with and inhibits the expression of human Beta catenin.
-
3. An antisense compound up to 30 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO:
- 8, 9, 11, 14, 15, 16, 18, 19, 20, 21, 22, 23, 24, 26, 27, 28, 29, 30, 31, 33, 34, 36, 38, 39, 40, 41, 42, 43, 44, 46, 47, 10, 12, 13, 17, 25, 35, 37 or 45 which inhibits the expression of human Beta catenin.
- View Dependent Claims (12, 13, 14, 15, 16, 17, 18, 19, 20)
Specification